Literature DB >> 28666722

Adjuvant pelvic radiation is associated with improved survival and decreased disease recurrence in pelvic node-positive penile cancer after lymph node dissection: A multi-institutional study.

Dominic H Tang1, Rosa Djajadiningrat2, Gregory Diorio3, Juan Chipollini3, Zhenjun Ma4, Braydon J Schaible4, Mario Catanzaro5, Dingwei Ye6, Yao Zhu6, Nicola Nicolai5, Simon Horenblas2, Peter A S Johnstone7, Philippe E Spiess3.   

Abstract

PURPOSE: Few studies have examined the role of radiation therapy in advanced penile squamous cell carcinoma. We sought to evaluate the association of adjuvant pelvic radiation with survival and recurrence for patients with penile cancer and positive pelvic lymph nodes (PLNs) after lymph node dissection.
MATERIALS AND METHODS: Data were collected retrospectively across 4 international centers of patients with penile squamous cell carcinoma undergoing lymph node dissections from 1980 to 2013. Further, 92 patients with available adjuvant pelvic radiation status and positive PLNs were analyzed. Disease-specific survival (DSS) and recurrence were analyzed using the Kaplan-Meier method and multivariable Cox proportional hazards model.
RESULTS: 43% (n = 40) of patients received adjuvant pelvic radiation after a positive PLN dissection. Median follow-up was 9.3 months (interquartile range: 5.2-19.8). Patients receiving adjuvant pelvic radiation had a median DSS of 14.4 months vs. 8 months in the nonradiation group, respectively (P = 0.023). Patients without adjuvant pelvic radiation were associated with worse overall survival (hazard ratio [HR] = 1.7; 95% CI: 1.01-2.92; P = 0.04) and DSS (HR = 1.9; 95% CI: 1.09-3.36; P = 0.02) on multivariable analysis. Median time to recurrence was 7.7 months vs. 5.3 months in the radiation and nonradiation arm, respectively (P = 0.042). Patients without adjuvant pelvic radiation was also independently associated with higher overall recurrence on multivariable analysis (HR = 1.8; 95% CI: 1.06-3.12; P = 0.03).
CONCLUSIONS: Adjuvant pelvic radiation is associated with improved survival and decreased recurrence in this population of patients with penile cancer with positive PLNs.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adjuvant radiation; Lymph node dissection; Penile cancer; Recurrence; Survival

Mesh:

Year:  2017        PMID: 28666722      PMCID: PMC7771352          DOI: 10.1016/j.urolonc.2017.06.001

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  19 in total

1.  Stage presentation, care patterns, and treatment outcomes for squamous cell carcinoma of the penis.

Authors:  Lindsay M Burt; Dennis C Shrieve; Jonathan D Tward
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-10-09       Impact factor: 7.038

2.  Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis.

Authors:  G Pizzocaro; L Piva
Journal:  Acta Oncol       Date:  1988       Impact factor: 4.089

3.  EAU guidelines on penile cancer: 2014 update.

Authors:  Oliver W Hakenberg; Eva M Compérat; Suks Minhas; Andrea Necchi; Chris Protzel; Nick Watkin
Journal:  Eur Urol       Date:  2014-11-01       Impact factor: 20.096

4.  Adjuvant chemotherapy is associated with improved overall survival in pelvic node-positive penile cancer after lymph node dissection: a multi-institutional study.

Authors:  Pranav Sharma; Rosa Djajadiningrat; Kamran Zargar-Shoshtari; Mario Catanzaro; Yao Zhu; Nicola Nicolai; Simon Horenblas; Philippe E Spiess
Journal:  Urol Oncol       Date:  2015-06-10       Impact factor: 3.498

5.  Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma.

Authors:  Carlos Bermejo; J Erik Busby; Philippe E Spiess; Lior Heller; Lance C Pagliaro; Curtis A Pettaway
Journal:  J Urol       Date:  2007-04       Impact factor: 7.450

6.  Neoadjuvant chemotherapy in advanced penile carcinoma.

Authors:  Joost A P Leijte; J Martijn Kerst; Evert Bais; Ninja Antonini; Simon Horenblas
Journal:  Eur Urol       Date:  2007-02-14       Impact factor: 20.096

7.  Penile cancer: Clinical Practice Guidelines in Oncology.

Authors:  Peter E Clark; Philippe E Spiess; Neeraj Agarwal; Matthew C Biagioli; Mario A Eisenberger; Richard E Greenberg; Harry W Herr; Brant A Inman; Deborah A Kuban; Timothy M Kuzel; Subodh M Lele; Jeff Michalski; Lance Pagliaro; Sumanta K Pal; Anthony Patterson; Elizabeth R Plimack; Kamal S Pohar; Michael P Porter; Jerome P Richie; Wade J Sexton; William U Shipley; Eric J Small; Donald L Trump; Geoffrey Wile; Timothy G Wilson; Mary Dwyer; Maria Ho
Journal:  J Natl Compr Canc Netw       Date:  2013-05-01       Impact factor: 11.908

8.  Role of radiation therapy in the treatment of carcinoma of the penis.

Authors:  R Ravi; H K Chaturvedi; D V Sastry
Journal:  Br J Urol       Date:  1994-11

9.  Prophylactic bilateral groin node dissection versus prophylactic radiotherapy and surveillance in patients with N0 and N1-2A carcinoma of the penis.

Authors:  J N Kulkarni; M R Kamat
Journal:  Eur Urol       Date:  1994       Impact factor: 20.096

10.  Role of paclitaxel and platinum-based adjuvant chemotherapy in high-risk penile cancer.

Authors:  Vanita Noronha; Vijay Patil; Vikas Ostwal; Hemant Tongaonkar; Ganesh Bakshi; Kumar Prabhash
Journal:  Urol Ann       Date:  2012-09
View more
  11 in total

1.  The relationship between HPV status and chemoradiotherapy in the locoregional control of penile cancer.

Authors:  Zhigang Yuan; Arash O Naghavi; Dominic Tang; Youngchul Kim; Kamran A Ahmed; Jasreman Dhillon; Anna R Giuliano; Philippe E Spiess; Peter A Johnstone
Journal:  World J Urol       Date:  2018-03-27       Impact factor: 4.226

2.  Primary Penile Cancer: The Role of Adjuvant Radiation Therapy in the Management of Extranodal Extension in Lymph Nodes.

Authors:  Peter A S Johnstone; David Boulware; Rosa Djajadiningrat; Sarah Ottenhof; Andrea Necchi; Mario Catanzaro; Dingwei Ye; Yao Zhu; Nicola Nicolai; Simon Horenblas; Philippe E Spiess
Journal:  Eur Urol Focus       Date:  2018-10-14

3.  Prognostic Factors of Penile Cancer and the Efficacy of Adjuvant Treatment after Penectomy: Results from a Multi-institution Study.

Authors:  Jong Won Kim; Young Sig Kim; Woo Jin Ko; Young Deuk Choi; Sung Joon Hong; Byung Ha Chung; Kwang Suk Lee
Journal:  J Korean Med Sci       Date:  2018-07-25       Impact factor: 2.153

Review 4.  Recent advances in the management of penile cancer.

Authors:  Maximilian J Johnston; Raj Nigam
Journal:  F1000Res       Date:  2019-04-26

5.  Adding radiotherapy based on chemotherapy can improve cancer-specific survival in N3 penile cancer: a SEER-based study.

Authors:  Wei-Kang Chen; Zhi-Gang Wu
Journal:  Transl Androl Urol       Date:  2020-12

6.  Impact of radiation therapy on perineal urethrostomy for penile cancer.

Authors:  Peter A S Johnstone; Hielke M de Vries; Juan Chipollini; G Daniel Grass; Franklin Boyd; Fernando Korkes; Maarten Albersen; Eduard Roussel; Yao Zhu; Ding-Wei Ye; Viraj Master; Thien-Linh Le; Asif Muneer; Oscar R Brouwer; Philippe E Spiess
Journal:  Clin Transl Radiat Oncol       Date:  2021-08-09

7.  Case report of penile cancer recurrence treated with cetuximab combined with anlotinib.

Authors:  Shuang Dai; Yan-Yang Liu; Tao Liu; Yu Zhang; De-Yun Luo
Journal:  Clin Case Rep       Date:  2022-02-15

Review 8.  Pelvic lymph node dissection alone versus adjuvant radiotherapy in node positive penile cancer: A systematic review.

Authors:  Naufa Naushad; Abdalla A Deb; Ayman A Agag; Hosam A Serag; Vijay K Sangar
Journal:  Indian J Urol       Date:  2022-04-01

9.  Intrinsic radiosensitivity, genomic-based radiation dose and patterns of failure of penile cancer in response to adjuvant radiation therapy.

Authors:  Zhigang Yuan; G Daniel Grass; Mounsif Azizi; Kamran A Ahmed; G Sean J Yoder; Eric A Welsh; William J Fulp; Jasreman Dhillon; Javier F Torres-Roca; Anna R Giuliano; Philippe E Spiess; Peter A Johnstone
Journal:  Rep Pract Oncol Radiother       Date:  2019-11-01

Review 10.  Penile cancer: a Brazilian consensus statement for low- and middle-income countries.

Authors:  Andrey Soares; Icaro Thiago de Carvalho; Aluízio Gonçalves da Fonseca; Antonio Machado Alencar; Carlos Heli Bezerra Leite; Diogo Assed Bastos; João Paulo Holanda Soares; Katia Ramos Moreira Leite; Mário Ronalsa Brandão Filho; Ronald Wagner Pereira Coelho; Sandro Roberto de A Cavallero; Stênio de Cassio Zequi; José de Ribamar Rodrigues Calixto
Journal:  J Cancer Res Clin Oncol       Date:  2020-10-26       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.